Cheaper keytruda alternative tested in lung cancer trial
NCT ID NCT06159790
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested GME751, a biosimilar (copy) of the immunotherapy drug Keytruda, against the original Keytruda in 218 adults with untreated advanced non-squamous lung cancer. The goal was to see if GME751 works as well and is as safe as Keytruda when combined with chemotherapy. The study is complete, and results will show if this biosimilar could be a more affordable treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GME751 (a biosimilar of pembrolizumab, also known as Keytruda)
What this could lead to
If successful, this could provide a more affordable alternative to Keytruda for treating advanced lung cancer, potentially expanding access to effective immunotherapy.
What could go wrong
This is a biosimilar, not a new drug, so it may not offer better outcomes than the original. The trial is completed but results are not yet widely available, and individual responses may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sandoz Investigational Site
Fountain Valley, California, 92708, United States
-
Sandoz Investigational Site
Banja Luka, Bosnia and Herzegovina
-
Sandoz Investigational Site
Sarajevo, Bosnia and Herzegovina
-
Sandoz Investigational Site
Zenica, Bosnia and Herzegovina
-
Sandoz Investigational Site
Belo Horizonte, Brazil
-
Sandoz Investigational Site
Fortaleza, Brazil
-
Sandoz Investigational Site
Ipatinga, Brazil
-
Sandoz Investigational Site
Porto Alegre, Brazil
-
Sandoz Investigational Site
São José do Rio Preto, Brazil
-
Sandoz Investigational Site
Batumi, Georgia
-
Sandoz Investigational Site
Tbilisi, Georgia
-
Sandoz Investigational Site
Rosenheim, Germany
-
Sandoz Investigational Site
Ahmedabad, India
-
Sandoz Investigational Site
Bhubaneswar, India
-
Sandoz Investigational Site
Hyderabad, India
-
Sandoz Investigational Site
Mumbai, India
-
Sandoz Investigational Site
Nagpur, India
-
Sandoz Investigational Site
Nashik, India
-
Sandoz Investigational Site
New Delhi, India
-
Sandoz Investigational Site
Varanasi, India
-
Sandoz Investigational Site
Asahikawa, Japan
-
Sandoz Investigational Site
Funabashi, Japan
-
Sandoz Investigational Site
Hiroshima, Japan
-
Sandoz Investigational Site
Kanazawa, Japan
-
Sandoz Investigational Site
Niigata, Japan
-
Sandoz Investigational Site
Okayama, Japan
-
Sandoz Investigational Site
Sapporo, Japan
-
Sandoz Investigational Site
Johor Bahru, Malaysia
-
Sandoz Investigational Site
Kuala Lumpur, Malaysia
-
Sandoz Investigational Site
Kuantan, Malaysia
-
Sandoz Investigational Site
Kuching, Malaysia
-
Sandoz Investigational Site
Malacca, Malaysia
-
Sandoz Investigational Site
Petaling Jaya, Malaysia
-
Sandoz Investigational Site
Putrajaya, Malaysia
-
Sandoz Investigational Site
Bacolod, Philippines
-
Sandoz Investigational Site
Cebu City, Philippines
-
Sandoz Investigational Site
Makati, Philippines
-
Sandoz Investigational Site
Cluj-Napoca, Romania
-
Sandoz Investigational Site
Floreşti, Romania
-
Sandoz Investigational Site
Kragujevac, Serbia
-
Sandoz Investigational Site
A Coruña, Spain
-
Sandoz Investigational Site
Córdoba, Spain
-
Sandoz Investigational Site
Madrid, Spain
-
Sandoz Investigational Site
Oviedo, Spain
-
Sandoz Investigational Site
Douliu, Taiwan
-
Sandoz Investigational Site
Kaohsiung City, Taiwan
-
Sandoz Investigational Site
Taichung, Taiwan
-
Sandoz Investigational Site
Taipei, Taiwan
-
Sandoz Investigational Site
Bangkok, Thailand
-
Sandoz Investigational Site
Khon Kaen, Thailand
-
Sandoz Investigational Site
Adana, Turkey (Türkiye)
-
Sandoz Investigational Site
Bursa, Turkey (Türkiye)
-
Sandoz Investigational Site
Gaziantep, Turkey (Türkiye)
-
Sandoz Investigational Site
Istanbul, Turkey (Türkiye)
-
Sandoz Investigational Site
Malatya, Turkey (Türkiye)
-
Sandoz Investigational Site
Sakarya, Turkey (Türkiye)
-
Sandoz Investigational Site
Yüreğir, Turkey (Türkiye)
-
Sandoz Investigational Site
Hanoi, Vietnam
-
Sandoz Investigational Site
Hà Nội, Vietnam
-
Sandoz Investigational Site
Ho Chi Minh City, Vietnam
-
Sandoz Investigational Site 2
Ahmedabad, India
-
Sandoz Investigational Site 2
Mumbai, India